Novo A/S partner joins Cytochroma board of directors
This article was originally published in Scrip
Cytochroma, a clinical-stage speciality pharmaceutical company, has appointed Dr Peter Moldt to its board of directors. He is a partner in Novo A/S, part of the Novo Nordisk Foundation, which he joined in 2009. Before that, Dr Moldt served as CEO of Curalogic, a development-stage biopharmaceutical company, and as chief operating officer of 7TM Pharma, a drug discovery company, both of which he co-founded. Dr Moldt has also worked with NeuroSearch, where he specialised in preclinical and clinical drug development. Dr Moldt will replace Ulrik Spork, who joined Cytochroma's board in 2008, also representing Novo A/S.
You may also be interested in...
The Indian pharmaceutical sector is recognised for its entrepreneurial spirit. Many companies have crafted successful business strategies by offering API manufacturing, drug discovery, CRAMS and other services to global pharmaceutical customers. Others market their products overseas while leveraging growth opportunities on their home turf. The following five domestic companies are well worth watching in 2011.
The Swedish biotech firm Active Biotech has appointed Dr Helén Tuvesson as its new chief scientific officer, effective 1 April. Dr Tuvesson has been with the company since 1998, working in preclinical development, R&D management and most recently within the senior management team. She will report to president and CEO Tomas Leanderson.
Affimed Therapeutics (Germany) has appointed Dr Adi Hoess as its new chief commercial officer. Effective immediately, Mr Hoess will focus on commercial and strategic management and business development, complimenting his previous senior management and business development roles at Jenowis, Carl Zeiss Jena, MorphoSys and Jerini. His appointment also coincides with the continued development of the company's lead product candidate, AFM13, for Hodgkin's lymphoma, which entered a Phase I clinical trial last November (scripintelligence.com, 15 November 2010).